# SciSparc Ltd. (SPRC)

> Source: Nexqual · https://nexqual.com/SPRC · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, SciSparc Ltd. (SPRC), nexqual.com/SPRC" · informational, not investment advice.

**Price:** USD 1.09 (-9.17% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 1.2 · day 1.07–1.21 · 52w 1.07–35.47 · market cap $633K · NCM

## Key facts
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $5K; 1 not under a Rule 10b5-1 plan ($5K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: None.
- Total return with dividends: 1Y -97.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Shrem Itschak | Director | 462 | $5K | 4.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -97.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -97.0% | -87.2% |
| Volatility (annualized) | 169.2% | 144.7% |
| Max drawdown | -97.0% (Oct 2025→Oct 2026) | -100.0% (Nov 2021→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/SPRC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in SPRC's own 20-F filed 2026-04-29 (https://www.sec.gov/Archives/edgar/data/1611746/000121390026049322/ea0286030-20f_scisparc.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | FedEx (FDX) | "the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services" |
| Supplier | UPS (UPS) | "the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services" |
| Customer | SciSparc Nutraceuticals | "of SciSparc Nutraceuticals to acquire or retain customers, and our efforts to sell new products or increase sales of our existing products," |
| Customer | Meta Platforms (META) | "Our customers may engage with us online through our social media platforms, including Facebook and Instagram," |
| Partner | Clearmind Medicine Inc. (CMND) | "For example, our collaboration with Clearmind Medicine Inc.," |
| Partner | Polyrizon Ltd. (PLRZ) | "In addition, in August 2024, we entered into an exclusive patent license agreement with Polyrizon Ltd.," |
| Partner | Amazon (AMZN) | "such as Amazon, which may result in an online retail partner removing the product from its marketplace." |
| Partner | Capital Point and Evero Health | "pursuant to a joint venture transaction entered into on May 15, 2020 by and between us, Capital Point and Evero Health Ltd. one of our" |
| Partner | AutoMax Motors | "the Israeli Police and the arrest of senior officials of AutoMax, we entered into a framework agreement with AutoMax on October 6, 2025" |
| Partner | Miza III Ventures | "into a definitive asset and share purchase agreement with Miza, a publicly traded company listed on the TSXV, pursuant to which we agreed" |
| Partner | Nexentis Technologies Inc. (NXTS) | "a securities purchase and exchange agreement with Nexentis Technologies Inc. ("Nexentis", formerly known as "N2OFF," |

Other companies that name SPRC in their own reports (relationship from SPRC's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Nexera Technologies Ltd (NEXR) | 20-F 2026-04-01 | "services are provided in collaboration with SciSparc." |
| partner | Polyrizon Ltd. (PLRZ) | 20-F 2026-03-25 | "August 13, 2024, we entered into an exclusive patent license agreement, or the SciSparc License Agreement, with SciSparc Ltd., or SciSparc," |
| partner | Clearmind Medicine Inc. (CMND) | 20-F 2026-01-20 | "ongoing collaboration with SciSparc, we entered into a research agreement with the Hebrew University of Jerusalem to evaluate our and" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2024-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |